Answers are grounded in this paper and cite their sources.
Conceptual review reports shared neurotoxin clearance deficits in Alzheimer's disease and glaucoma, suggesting that glymphatic dysfunction underlies both neurodegenerative disorders.
We read with great interest the review by Prins et al. (2016) entitled ‘Structural brain MRI studies in eye diseases: are they clinically relevant? A review of current findings’ published recently in Acta Ophthalmologica. We would like to comment on their valuable article while presenting an additional viewpoint. In one section of their paper, Prins et al. (2016) discuss the possible link between glaucoma and Alzheimer's disease (AD). The authors note that ‘….some researchers suggest an association between Alzheimer's disease and glaucoma. Glaucoma and Alzheimer's disease share several characteristics: they are both neurodegenerative, chronic, progressive, age-related and associated with irreversible neuronal cell loss. This may indicate that glaucoma and Alzheimer's disease are connected through the same underlying pathologic mechanism….’. The authors also gave directions for future research. They state that ‘Future structural brain MRI studies are needed to assess whether MRI examination can be a useful diagnostic tool in certain eye diseases’. We fully agree with both notions. Our group recently proposed that glaucoma, just like AD, may occur when there is an imbalance between production and clearance of neurotoxins, including amyloid-β (Aβ) that is a hallmark protein in AD (Wostyn et al. 2014, 2015). Previous findings at least suggest that high intraocular pressure may generate inflammatory proteins and neurotoxins, such as Aβ, via mechanosensitivity that could then be cleared via the cerebrospinal fluid (CSF) (Wostyn et al. 2014). Interestingly, recent insights into the physiology of CSF circulation may shed new light on the link between AD and glaucoma. In particular, Iliff et al. (2012) have recently proposed the existence of a brain-wide network of paravascular channels, which they termed the ‘glymphatic’ pathway, along which a large proportion of subarachnoid CSF recirculates through the brain parenchyma, facilitating the clearance of interstitial solutes, including Aβ, from the brain. One implication is that glymphatic pathway dysfunction may contribute to the deficient Aβ clearance in the preclinical stages of AD (Yang et al. 2013). We believe that the glymphatic system may also be of important relevance for the understanding of glaucoma and its association with AD (Wostyn et al. 2015). In light of the key role that the glymphatic pathway may play in the clearance of interstitial solutes and metabolic wastes from the brain, this knowledge could be of great importance for our understanding of how solutes are cleared from the interstitial fluid (ISF) in the optic nerve. The optic nerve, a white matter tract of the central nervous system (CNS), is ensheathed in all three meningeal layers and surrounded by CSF in the subarachnoid space (SAS) (Wostyn et al. 2015). The SAS of the optic nerve is contiguous with the SAS of the brain. Previous studies investigating the flow of fluids in the anterior part of the optic nerve at least sugg-est some level of exchange between the ISF of the optic nerve and the surrounding CSF (Wostyn et al. 2014, 2015). Given that the optic nerve is a white matter tract extending from the brain, and given the remarkable similarities between these two parts of the CNS, it would be very interesting to investigate whether a similar glymphatic pathway for CSF-ISF exchange exists in the optic nerve. Even if this is not the case, there may be an interconnection between the glymphatic pathway of the brain and the SAS of the optic nerve, which in turn may facilitate efficient CSF-ISF exchange in the optic nerve, allowing clearance of interstitial solutes, including Aβ. Exploring this possibility could lead to a new understanding of the pathogenesis of glaucoma. Indeed, if confirmed, one might expect that a dysfunctional glymphatic system of the brain could ultimately result in reduced neurotoxin clearance in the optic nerve and lead to glaucomatous neurodegeneration. Moreover, glymphatic pathway dysfunction as a potential mechanistic link between AD and glaucoma is an attractive hypothesis as this could explain the reported comorbidity of the two disorders. Obviously, further studies are needed to determine whether failure of this clearance system may explain the clinical overlap of AD and glaucoma. Interestingly, as a clinically acceptable MRI-based approach to evaluate glymphatic pathway function in humans has recently been developed (Yang et al. 2013), a unique opportunity now exists to investigate whether suppression of the glymphatic system contributes to the development of both disorders.
No takes yet. Share an insight, caveat, or question.
Wostyn et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: